Free Trial

Dr. Martens (DOCS) Competitors

Dr. Martens logo
GBX 79.15 +0.35 (+0.44%)
As of 07/18/2025 11:58 AM Eastern

DOCS vs. TEM, RMG, VTY, SPT, GEN, WIX, YOU, CNIC, SRAD, and SLP

Should you be buying Dr. Martens stock or one of its competitors? The main competitors of Dr. Martens include Templeton Emerging Markets Investment Trust (TEM), Royal Mail (RMG), Vistry Group (VTY), Spirent Communications (SPT), Genuit Group (GEN), Wickes Group (WIX), YouGov (YOU), CentralNic Group (CNIC), Stelrad Group (SRAD), and Sylvania Platinum (SLP). These companies are all part of the "computer software" industry.

Dr. Martens vs. Its Competitors

Dr. Martens (LON:DOCS) and Templeton Emerging Markets Investment Trust (LON:TEM) are both computer software companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Dr. Martens presently has a consensus price target of GBX 6,000, suggesting a potential upside of 7,480.54%. Given Dr. Martens' stronger consensus rating and higher probable upside, analysts clearly believe Dr. Martens is more favorable than Templeton Emerging Markets Investment Trust.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dr. Martens
0 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Templeton Emerging Markets Investment Trust
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Templeton Emerging Markets Investment Trust has lower revenue, but higher earnings than Dr. Martens. Dr. Martens is trading at a lower price-to-earnings ratio than Templeton Emerging Markets Investment Trust, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dr. Martens£874.20M0.88£68.97M£7.0511.22
Templeton Emerging Markets Investment Trust£160.96M12.74£130.50M£12.4715.73

69.5% of Dr. Martens shares are held by institutional investors. Comparatively, 71.1% of Templeton Emerging Markets Investment Trust shares are held by institutional investors. 4.4% of Dr. Martens shares are held by company insiders. Comparatively, 0.6% of Templeton Emerging Markets Investment Trust shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Dr. Martens pays an annual dividend of GBX 3 per share and has a dividend yield of 3.8%. Templeton Emerging Markets Investment Trust pays an annual dividend of GBX 6 per share and has a dividend yield of 3.1%. Dr. Martens pays out 42.5% of its earnings in the form of a dividend. Templeton Emerging Markets Investment Trust pays out 48.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Dr. Martens is clearly the better dividend stock, given its higher yield and lower payout ratio.

Templeton Emerging Markets Investment Trust has a net margin of 81.07% compared to Dr. Martens' net margin of 7.89%. Dr. Martens' return on equity of 18.91% beat Templeton Emerging Markets Investment Trust's return on equity.

Company Net Margins Return on Equity Return on Assets
Dr. Martens7.89% 18.91% 8.12%
Templeton Emerging Markets Investment Trust 81.07%7.07%4.50%

Dr. Martens has a beta of 0.11, indicating that its stock price is 89% less volatile than the S&P 500. Comparatively, Templeton Emerging Markets Investment Trust has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500.

In the previous week, Dr. Martens had 4 more articles in the media than Templeton Emerging Markets Investment Trust. MarketBeat recorded 6 mentions for Dr. Martens and 2 mentions for Templeton Emerging Markets Investment Trust. Templeton Emerging Markets Investment Trust's average media sentiment score of 1.26 beat Dr. Martens' score of 0.83 indicating that Templeton Emerging Markets Investment Trust is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Dr. Martens
3 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Templeton Emerging Markets Investment Trust
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Dr. Martens beats Templeton Emerging Markets Investment Trust on 9 of the 17 factors compared between the two stocks.

Get Dr. Martens News Delivered to You Automatically

Sign up to receive the latest news and ratings for DOCS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DOCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DOCS vs. The Competition

MetricDr. MartensFootwear & Accessories IndustryCyclical SectorLON Exchange
Market Cap£768.36M£10.32B£3.48B£3.02B
Dividend Yield1.36%1.71%3.54%5.02%
P/E Ratio11.2218.5571.98165.88
Price / Sales0.8832.2471.66285,132.26
Price / Cash14.2920.2831.1627.97
Price / Book2.093.863.784.46
Net Income£68.97M£168.67M£264.31M£5.90B
7 Day Performance0.19%-1.07%-0.27%3.84%
1 Month Performance6.17%2.76%2.73%10.33%
1 Year Performance9.47%-8.05%2,623.59%75.55%

Dr. Martens Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DOCS
Dr. Martens
3.5363 of 5 stars
GBX 79.15
+0.4%
GBX 6,000
+7,480.5%
+9.5%£768.36M£874.20M11.22890Dividend Cut
Gap Down
TEM
Templeton Emerging Markets Investment Trust
N/AGBX 195.58
+1.0%
N/A+18.8%£2.04B£160.96M15.68N/APositive News
RMG
Royal Mail
N/AN/AN/AN/A£1.98B£12.71B339.34100
VTY
Vistry Group
1.9441 of 5 stars
GBX 595
-0.3%
GBX 631
+6.1%
-54.5%£1.94B£3.55B7.914,400News Coverage
Analyst Forecast
SPT
Spirent Communications
1.4903 of 5 stars
GBX 195.60
+0.3%
GBX 236
+20.7%
+9.7%£1.40B£561.21M105.741,526
GEN
Genuit Group
N/AGBX 390
+0.3%
GBX 520
+33.3%
-17.7%£967.32M£553.28M40.922,700
WIX
Wickes Group
2.3623 of 5 stars
GBX 222
-0.9%
GBX 215
-3.2%
+61.1%£525.63M£1.45B17.955,930News Coverage
YOU
YouGov
3.0737 of 5 stars
GBX 334.50
-4.4%
GBX 760
+127.2%
-29.4%£391.41M£335.28M-170.471,820Gap Up
CNIC
CentralNic Group
N/AN/AN/AN/A£339.82M£790.04M-12,660.00100
SRAD
Stelrad Group
N/AGBX 171.81
-1.8%
N/A+31.0%£228.25M£306.97M14.762,960Gap Up
SLP
Sylvania Platinum
3.8668 of 5 stars
GBX 68.60
+1.2%
GBX 93
+35.6%
+15.7%£221.39M£99.97M32.15160News Coverage
Positive News

Related Companies and Tools


This page (LON:DOCS) was last updated on 7/20/2025 by MarketBeat.com Staff
From Our Partners